Online inquiry

IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6059MR)

This product GTTS-WQ6059MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCL2 gene. The antibody can be applied in Pulmonary Fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002982.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6347
UniProt ID P13500
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6059MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3225MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ13403MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ1220MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ12133MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ743MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ2456MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ8160MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ8902MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IGE25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW